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Abstract
Background
UK National Guidelines (UKNG) advise HIV testing in clinically indicated neurological pre-
sentations. We audited the impact of our practical strategies to increase uptake of HIV test-
ing at a regional acute neurology admissions unit.
Methods
We audited HIV testing in 4 periods over 2 years: before we designed a UKNG-based “HIV
testing in Neurology” protocol (“pre-protocol”); after dissemination of the protocol alone
(“post-protocol”); post-protocol dissemination combined with both a tailored departmental
admissions clerking proforma to prompt for HIV testing & consenting, and regular focussed
tutorials to doctors on HIV testing in neurological patients (“post-proforma”); and finally one
year after the post-proforma period (“+1 year”). We also looked at the total number of HIV
tests sent from the unit during the two-year period. We assessed significance using Fisher’s
exact test.
Results
47.8% of all acute neurology non-stroke admissions were eligible for HIV testing during all
the audit periods. Testing rates were as follows: pre-protocol 21.9%; post-protocol 36.6%;
post-proforma 83.3%; and at +1 year 65.4% (p<0.05 for both post-protocol and +1 year
when compared to pre-protocol). Documentation of consent for HIV testing improved
from 25% to 67.6% with the HIV-tailored clerking proforma. The total number of HIV tests
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requested from the unit doubled in the post-proforma period compared to pre-protocol
(p<0.05).
Conclusion
In conclusion: the combination of an HIV testing protocol, a tailored departmental clerking
proforma and regular focussed teaching to doctors on indications for HIV testing led to a
sustained increase in HIV testing uptake in our regional acute neurology admissions unit.
Introduction
The prevalence of Human Immunodeficiency Virus (HIV) infection in the UK has increased
by 25% over five years to an estimated 98,400 people [1]. Early diagnosis is vital as commenc-
ing combined anti-retroviral therapy before severe immunosuppression can lead to a near-nor-
mal life expectancy [2, 3]. Early knowledge of HIV status also helps change behaviour that
reduces HIV transmission to partners [4, 5], which has sizeable health-cost savings: prevention
of one HIV infection saves approximately £0.3 million of public funds [6]. Yet one in five, and
in some high-risk groups up to a third, of people with HIV are unaware of their diagnosis in
the UK [1]. Those diagnosed “late” with HIV (CD4<350 cells/uL) have a worse prognosis [7],
and up to a quarter of deaths can be attributed to missed opportunities by healthcare workers
to test at an earlier stage [8, 9].
Opt-out HIV testing in all patients is recommended in the USA [10]. The UK National
Guidelines for HIV testing (UKNG) 2008 were developed to help normalise and expand HIV
testing across healthcare services [11]. Testing all hospitalised patients for HIV, regardless of
local prevalence and risk factors, is feasible and cost-effective in the UK and well accepted
amongst patients [12–14]. However, the UKNG advocate routine testing only where local diag-
nosed prevalence is 2/1000 or greater.
Opt-out routine testing rates in “traditional” settings such as sexual health and ante-natal
clinics have increased substantially since the UKNG [15]. There has also been some success in
other “non-traditional” settings in the UK and Europe [16–28] (see Table 1).
Dissemination of UKNG using conventional methods alone–presenting at medical “grand
rounds”, via letter and email, posting guidelines on wards and doctors’ offices–has been shown
to have little impact on uptake of HIV testing even in high sero-prevalent areas such as London
and Blackpool [19, 22]. More robust publicity, providing multi-lingual patient information
leaflets, focussed tutorials for frontline testing staff, admission proforma prompts for HIV test-
ing, regular on-site support by HIV staff, and using trained individuals to obtain consent and
blood samples have been shown to be more successful [16–18, 20, 21].
The UKNG clinical indicator conditions include neurological presentations of HIV infec-
tion. HIV enters the nervous system early during acute infection and can affect any part of the
nervous system; 10% of HIV sero-conversion presentations are neurological, usually as an
aseptic meningo-encephalitis [29]. Therefore, a pure neurological presentation of HIV is an
opportunity to diagnose the infection at an early stage; indeed, it is recommended to test for
HIV in all patients with suspected encephalitis [30].
The Department of Clinical Neurology in Sheffield, South Yorkshire, is a tertiary centre
which admits patients with acute neurological presentations, including strokes. There are
approximately 3,500 acute admissions per year, of which 50–60% are discharged within
48 hours (cases such as uncomplicated exacerbations of seizures, acute headaches, multiple
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sclerosis relapses and medical decompensation of chronic neurological disorders). The preva-
lence of HIV in Yorkshire has trebled over the last decade, and Sheffield’s HIV prevalence has
risen from 1.4 to 1.8/1000 [31]. In late 2010 a middle-aged patient was transferred from a dis-
trict general hospital, but the HIV-related diagnosis causing the neurological decline was not
realised until three months later, at which point their CD4 count was 13. This prompted collab-
oration with the local Genito-Urinary Medicine department to improve HIV testing in eligible
acute neurology patients, and a local “HIV Testing in Neurology” protocol was devised, based
on the UKNG (Fig 1).
Materials and Methods
We prospectively reviewed medical notes for patients admitted as acute non-stroke neurology
cases over four time periods:
Table 1. Summary of studies aimed at improving HIV testing uptake in “non-traditional” settings.
Study: Setting Pre-study interventions Study Periods Results HIV
+ve
Ellis et al, 2011 [16]: acute
medical admissions
(Newcastle)
Specialist-led seminar and tutorials, pre-
test patient leaﬂet, 1-page HIV proforma
14th September–26th October 2009:
Junior doctors did 91.1% of tests; 4th
January–19th March 2010: Clinical
assistant did 78.9% of tests
478/3753 approached
(12.7%); 396/478
consented (82.8%)
2
Palfreeman et al, 2013 [17]:
Acute Medical Admissions
Unit (Leicester)
Consultants emailed, junior doctors’
induction, AMU staff trained
“Pre-pilot”: September 2008–August
2009
205/5484 tested (3.7%) 4
Additionally: patient posters, multi-lingual
leaﬂets, clerking proforma tailored for HIV
testing
“Pilot”: September 2009—August
2010 (weekly visit by HIV physician to
AMU)
937/5517 tested (17.0%) 10
“Post-pilot”: September 2010-August
2011 (no further interventions)
1399/6225 tested (22.5%) 15
Phillips et al, 2014 [18]:
Acute Medical Admissions
Unit (Croydon)
Specialist-led seminar and tutorials,
consultants emailed, juniors’ induction,
AMU staff trained, intranet updates,
patient posters and admission packs,
HIV-tailored proforma
Jul 2011 –Mar 2013 Weekly visits to
AMU by HIV team for ﬁrst 3 months
4122/12682 tested (32.5%) 14
Peck et al, 2010 [19]: Acute
Admissions Unit (UCL,
London)
Intranet guideline, consultants informed,
trainees tutorial
15th April–18th July 2008 16/56 tested (28.6%) 1
Rayment et al, 2012 [20] HIV
in non-traditional settings (the
HINTS study): all study sites
in London
(Chelsea & Westminster Emergency
Department) Seconded staff, sexual
health department support, non-clinical
testers
August–November 2009 3433/5505 approached
(62.4%); 2121/3433
consented (61.8%)
4
(Homerton Acute Care Unit) Seconded
staff from various departments
January–April 2010 548/1298 approached
(42.2%); 384/548
consented (70.1%)
4
(Kings College Dermatology clinic) Two
student HIV testers offering test pre-clinic
July–September 2010 1329/5352 approached
(24.8%); 1002/1329
consented (75.4%)
0
(North End Primary Care Medical Centre)
Practice clinical staff had focussed
training; testing introduced in a staggered
fashion
February—May 2010 884/1700 approached
(52%); 598/884 consented
(67.6%)
0
Perry et al, 2010 [27]: Acute
General Medicine (Brighton)
August–December 2009 1190/2735 tested (43.5%) 2
Alston et al, 2013 [28]: Acute
admissions (Surrey &
Sussex)
2011 1% in high-prevalence
areas; 3% in low-
prevalence areas (out of
200 case notes reviewed)
?
doi:10.1371/journal.pone.0134574.t001
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1. “Pre-protocol”, 30th July–31st August 2012: before the protocol was first disseminated to
clinical staff;
2. “Post-protocol”, 19th October–10th November 2012: after the protocol was emailed to all
departmental consultants and frontline staff, and copies placed on ward noticeboards, in
doctors’ offices and on notes trolleys;
3. “Post-proforma”, 10th June 2013–1st August 2013: 2 months after altering the neurology
departmental clerking proforma to prompt on consenting and testing for HIV in eligible
patients. We did this by adding the questions “Is HIV testing indicated? Yes/No” and “If
indicated, consent obtained? Yes/No” into the mandatory statements section (this section
also includes prompts for venous thromboprophylaxis, decision for resuscitation proce-
dures and cognitive screening). Implementation of the new proforma in April 2013 coin-
cided with the rotation of new junior doctors starting at the hospital. At the hospital
induction, we educated doctors about the importance of HIV testing in acute neurology
patients and reinforced this with a focussed tutorial in May 2013.
4. “+ 1 year”, 28th May–20th July 2014: we continued with the interventions of stage (3.) above
every doctors’ rotation, and re-audited at the end of one year.
We aimed to review a minimum of 60 case-notes during each audit period after the protocol
was disseminated, and collected data as to whether:
1. the patient was eligible for an HIV test;
2. the HIV test was undertaken, and if so what the result was;
3. consent was documented;
4. the eventual diagnosis was an indicator condition.
In addition, in order to measure the effect of our interventions on overall uptake of HIV
testing within our acute neurology service, we cross-referenced all HIV tests undertaken within
the hospital Trust, held on a database by the Department of Virology, with our electronic data-
base of all acute admissions including stroke for the period 1st June 2012–31st August 2014.
All data were inputed and analysed on Microsoft Excel.
Ethical Approval
The project was a service evaluation and quality improvement initiative by the Sheffield Teach-
ing Hospitals NHS Foundation Trust Clinical Effectiveness and Audit Unit (CEAU). Formal
ethical approval by the local research ethics board was therefore not required.
Patient Consent
We strictly adhered to the UKNG for patient consent during HIV testing: indications for HIV
testing were explained to all patients before undertaking the test, and for those patients who
lacked capacity at the time of testing, a medical decision was made based on the patient’s best
interests. As per UKNG guidelines, consent was documented in the acute admissions clerking
Fig 1. The Sheffield “HIV Testing in Neurology” protocol. Based on the UKNGGuidelines for HIV testing.
We have previously presented preliminary data from an audit of the effectiveness of this protocol alone in
improving HIV testing [32]. We evaluated efficacy of improving HIV testing in eligible patients by re-auditing
our service after changing the neurology admission proforma and introduced training sessions. We also
studied the total number of HIV tests sent from the acute neurology unit.
doi:10.1371/journal.pone.0134574.g001
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proforma using “Yes/No” answers. For those patients who lacked capacity to consent for HIV
testing but in whom testing was definitely indicated, the test was still undertaken by the consul-
tant’s team if it was deemed to be in the best interests of the patient.
The CEAU indicated that specific consent for this service evaluation study was not required
as we were following local Trust guidelines on information governance and patient confidenti-
ality including in the context of “sensitive diseases” such as HIV. The procedures for consent
for HIV testing as above were accepted by the CEAU.
We followed the SQUIRE Guidelines (www.equator-network.org) throughout this quality
improvement study. The project was in keeping with the principles of the Declaration of
Helsinki.
Results
There were 6723 admissions over 2 years and 2 months: 4349 (64.6%) were acute non-stroke
neurology admissions, 928 (13.8%) were acute stroke admissions, and the rest were elective
admissions. All patients approached for HIV testing accepted to have the test, giving a patient
uptake rate of 100%. There were no positive HIV tests throughout the audit period.
Table 2 summarises the results of the audit, and the diagnoses of patients in whom HIV test
was indicated are shown in Table 3. “Post-protocol” testing of eligible patients was higher at
36.6% compared to 21.9% during the “pre-protocol” period, and highest during the “post-pro-
forma” period at 83.3% but this reduced to 65.4% at “+1 year”. Overall HIV testing rates during
the casenotes audit periods (and for all admissions) consistently increased through the two
years, from 12.3% (9.0% for all admissions) during “pre-protocol”, to 18% (20.4%) during
“post-protocol”, then to 33.9% (23.4%) during “post-proforma” and finally to 28.3% at “= 1
year”. 70 of the 80 eligible patients during the casenotes audit period had UKNG clinical indi-
cator diseases.
Table 2. Results of the four stages of the audit.
“Pre-Protocol” “Post-Protocol” “Post-Proforma” “+1 year”
Admissions 1
Jun–31 Aug 2012
Audit 30
Jul–31 Aug
2012
Admissions 1 Sep
2012–2 Apr 2013
Audit 19
Oct–10 Nov
2012
Admissions 3 Apr
2013–1 Aug 2014
Audit 10
Jun–1 Aug
2013
Audit 28
May–20 Jul
2014
Patients admitted 392 136 1109 111 2848 120 119
Patients admitted
>48 hours
201 73 481 61 1120 59 60
Median age in
years (range)
53(20–87) 52 (17–95) 53 (16–90) 59 (28–95)
HIV test
indicated
41 30 24 26
HIV test
performed
18 9 98 11 262 20 17
Consent
documented
0 5 15 10
Overall testing
rate
9.0% a,b 12.3% 20.4% a 18.0% 23.4% b 33.9% 28.3%
Eligible testing
rate
21.9% c,d 36.6% e 83.3% c,e 65.4% d
Two-tailed Fisher’s exact test statistically signiﬁcant at p<0.05 when comparing:
a-b overall HIV testing rates between the “pre-proforma” and both “post-proforma” (a) and “post-protocol” (b) periods
c-e proportion of HIV testing in eligible patients during case-notes audit between: “pre-proforma” and “post-protocol” (c); “pre-proforma” and “+1 year”; and
“post-proforma” and “post-protocol” (e) periods
doi:10.1371/journal.pone.0134574.t002
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Discussion/Conclusion
This is the first study investigating the effect of practical simple interventions to improve HIV
testing uptake in neurology patients, whom are an important group as they include several con-
ditions that can be result of acute seroconversion and chronic HIV infection. Compared to
similar studies in other non-traditional settings (Table 1), we additionally measured the sus-
tained effect of our interventions with a fourth stage of re-audit.
47.8% of our patients during the audit periods were eligible for HIV testing, compared to
15–28% of unselected acute medical admissions presenting with neurological problems [18,
33], which reflects the nature of acute neurological cases presenting to our neurology unit. The
overall testing rate for all patients after introduction of the protocol, assuming a similar eligibil-
ity rate for testing throughout the post-protocol period, came to 19% which is comparable to
other studies. Dissemination of the HIV testing protocol on its own increased uptake by a mod-
est 15%, similar to previously reported studies [19, 22], although this is better than having no
departmental UKNG-based protocol as a recent study of HIV testing in intensive care patients
within our hospital Trust found a testing rate of<5% in eligible patients [34].
The proportion of eligible acute neurology and stroke patients who were tested for HIV
doubled from the pre-protocol period to 20.4%, and continued to increase in the final audit
period to 23.4%. The combined effect of our protocol, regular focussed teaching for admitting
staff, and altering the admission clerking proforma increased testing uptake 3.7-fold to a maxi-
mum of 83%. The effect was sustained at a lower rate of 65% when audited one year later; this
is comparable to 66.8% from the HINTS study [20]. This plateauing effect has been seen e.g. in
the Croydon study, where after the initial intensive period of training clinical staff the rate
peaked to 41.3% but then settled to 32.5% [18], partly attributed to the rapid turnover of staff
in acute medical settings. (The testing rates during our case-notes audit period are almost twice
as high as those reported in other acute settings probably due to the smaller numbers of cases
[16–18, 27]). Since the “post-proforma” period, the HIV testing protocol is included as manda-
tory introductory material for junior doctors during our departmental induction session at the
Table 3. Clinical presentations of patients eligible for HIV based on the Sheffield testing protocol.
Unexplained peripheral neuropathy 15
Leukoencephalopathy / atypical demyelination 13
Encephalitis 9
Transverse Myelitis 7
Space occupying lesion of unknown cause 7
Guillain-Barre syndrome 7
Myositis 5
Atypical dementia 4
Aseptic meningitis 3
Other:
Atypical optic neuritis a 4
Unexplained ataxia b 3
Complicated headaches c 3
Total 80
a as deﬁned by the “atypical optic neuritis” protocol (see discussion section)
b as a national ataxia centre, HIV testing was done on these patients after applying our departmental ataxia
investigation panel
c headaches with cranial nerve involvement or other neurological features
doi:10.1371/journal.pone.0134574.t003
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begin of their rotation. However, we found that one of the key interventional differences
between the “post-proforma” and “+1 year” periods was that the focussed training of junior
doctors regarding HIV testing was occurring towards the middle or end of their rotation in the
“+1 year” period, rather than towards the beginning as was the case during the “post-pro-
forma” period. The co-incident induction and focussed teaching during the post-proforma
probably had a synergistic effect to increasing awareness of HIV testing amongst the new
junior doctors. Therefore, to counter the plateauing effect, we will ensure that the focussed
teaching returns to occurring within the first few weeks of the start of the rotation.
In the “post-protocol” period, the overall testing rate was 23.4% but in the audit period was
slightly higher at 33.9%. This could be as a result of the more active interventions (focussed
seminars and teaching sessions, awareness of the role out of the new proforma) in addition to
the relatively passive intervention of disseminating the HIV testing protocol. These more
dynamic interventions are more likely to have enthused the new house of junior medical staff
during the audit period which is reflected in the high number of cases tested for HIV; such
effects have been noted in other studies [17, 18]. This may also be the reason why 100% of
patients approached consented to have their HIV status checked, as compared to 61.8%-82.8%
acceptance rates in other studies [16, 20]. Taking the quoted estimated HIV prevalence of
approximately 2 per 1000 in South Yorkshire, we would have expected to have 4 patients tested
positive. No new HIV cases were encountered during our study period. This could be because:
1. acute general medical admissions are admitted at another city hospital, therefore acute
patients with HIV clinical indicator diseases in whom the neurology component is not a
dominant feature would by-pass our unit and be tested for HIV elsewhere;
2. patients admitted to district general hospitals with acute neurological problems are some-
times managed by neurologists without transfer to our unit;
3. despite the increase in HIV testing uptake through our interventions, over half of test-eligi-
ble patients were still not tested and therefore could have been missed.
Details of all patients who met local guidelines for HIV test but who were not tested were
fed back to their respective neurology consultants for follow-up. It is important that screening
continues, as one missed case is costly to public health funds [6]. Moreover, neurological
admissions in general are varied and often result in many expensive tests, frequently with a
poor return of positive diagnoses e.g. one component of a full vasculitis screen [35].
Barriers to testing for HIV perceived by frontline staff were not investigated in this study,
but feedback revealed factors similar to previous studies: HIV stigma [36], variability of uptake
amongst consultants [17], inadequate financial and workforce infrastructure [37], and per-
ceived inadequate skill set [20]. The last factor was particularly apparent during the junior doc-
tor teaching sessions, and it has been shown that despite HIV medicine being on the 2009
national core curriculum, over two-thirds of junior doctors still feel they need further training
to confidently test for HIV [28, 38].
As with previous studies, our patients were mostly above the age of 50 years [18], in our
case the upper limit of the age range being above 80 years as we did not dictate an age ceiling.
Previous studies that did so eventually revised their age range of test eligibility: in the Leicester
study, all patients newly diagnosed with HIV were above the age of 45 years [17], and three
newly diagnosed HIV patients were above the age of 59 in the Croydon study [18]. This rein-
forces the importance of considering testing in older patients, as they are most likely to be late
presenters and be missed for opportunistic HIV testing as they do not necessarily fall into
“high-risk” categories [26, 33, 39].
HIV Testing in Neurology
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The printed prompt for HIV testing (along with consent) in the neurology clerking pro-
forma improved documentation of consent from 25% to 67.6%, but overall consent was poorly
documented at an average of 35.1% whereas the UKNGmandate documentation of consent in
every patient. A similar audit in another study had a rate of 58% [19].
1 in 8 of our test-eligible patients had conditions not specifically listed in the clinical indica-
tor list. Three patients had unexplained ataxia; our hospital is a national centre of excellence
for ataxia, and pure cerebellar dysfunction as a complication of HIV infection have been
described [40]. Four patients were tested as they presented with atypical optic neuritis, as
defined by local guidelines developed by our neuro-opthalmology service which recommends
appropriate serology testing in such cases [41]. Three patients had complicated presentations
of headache, including one case with meningism and low-grade fever, one case with cranial
neuropathies and one with ophthalmoplegia not due to acute stroke. In other similar studies,
42–50% of patients who tested positive for HIV had a presentation not listed as an indicator
condition, including presenting with acute headache [17, 18]. Given 10% of acute sero-conver-
sion can present with meningitic or encephalitic features, there is rationale to include routine
testing for HIV in acute non-primary headaches [29].
The data from overall HIV testing rates showed there were 23 HIV tests, approximately one
a month, requested from stroke admissions. We did not audit HIV testing in acute stroke
admissions in our study, but there are recommendations for HIV testing in all acute stroke
patients, particularly in younger patients and cryptogenic cases [42]. We also did not audit
HIV testing in neurology outpatients during our study as we were looking at acute admissions.
Only one previous study looked at outpatient HIV testing in primary care and outpatient set-
tings [20]. Our HIV testing protocol is readily available in our outpatients section, and our
work has been presented within the department to consultants, registrars and junior doctors
who work in clinics in order to reinforce HIV testing in the non-acute patients.
In conclusion, we have demonstrated that a combination of pragmatic interventions has led
to a significantly sustained increase of HIV testing in eligible patients admitted to an acute neu-
rology unit in an area with low HIV prevalence. We have shown that nearly one half of all
acute neurology admissions merit HIV testing according to local guidelines. We strongly rec-
ommend all centres that admit acute neurology cases adopting similar interventions for oppor-
tunistic HIV testing in order to avoid missing neurological presentations of HIV. We also
suggest extending interventions (along with audit) into neurology outpatient settings as we
have to increase HIV testing in non-acute patients.
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